Medicinal Cannabis NZ Guide

How to read medicinal-cannabis evidence

Reading medicinal-cannabis evidence is not like reading evidence for a single drug.

How to read medicinal-cannabis evidence
Medicinal Cannabis NZ Guide , CC BY 4.0 via Wikimedia Commons

Reading medicinal-cannabis evidence is not like reading evidence for a single drug. A cannabis preparation is not one medicine; it is a combination of active compounds, a route of administration, a dose, and a specific condition. When you read a study or a claim, separate four things before you judge whether it applies to you or your patient: the condition being treated, the outcome measured, the preparation used, and the quality of the evidence. If any of these four is missing, the claim is incomplete and should not guide a prescribing decision.

Every useful statement about medicinal cannabis must name the condition, the outcome, the preparation, and the evidence quality, or it is marketing, not evidence.

How to read medicinal-cannabis evidence: The four-question rule

Every useful statement about medicinal cannabis should answer four questions:

  1. Which condition? (e.g., chronic neuropathic pain, not “pain”)
  2. Which outcome? (e.g., 30% reduction in pain score, not “feels better”)
  3. Which preparation? (e.g., CBD oil 10 mg/mL, THC flower 22%, not “cannabis”)
  4. What evidence quality? (e.g., systematic review, RCT, expert opinion, anecdote)

If a claim cannot answer all four, treat it as marketing, not evidence.

Regulatory frame

What the Medicinal Cannabis Scheme actually allows

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, not a general licence to use cannabis. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), legalises access via a prescription from a medical practitioner. Preparations must meet GMP standards and be approved by the Ministry of Health (New Zealand Ministry of Health, 2020). The scheme does not legalise recreational use, home growing, or the purchase of unregulated items. A prescription is required for all medicinal cannabis preparations, including CBD-only options, and the raw flower is prescribed and dispensed through a pharmacy, not a dispensary.

The most common error newcomers make is assuming “legal medicinal cannabis” means they can smoke raw plant material or buy unregulated oils. Under the Medicinal Cannabis Scheme, the legal item is a manufactured pharmaceutical that meets GMP standards and is approved by the Ministry of Health.

Key dates and legal instruments

  • The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018.
  • The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set out the legal framework from 31 January 2020.
  • The scheme began accepting licence applications on1 April2020.
  • The Ministry of Health runs the scheme through the Medicinal Cannabis Agency (MCA).
  • The Minister of Health can set a maximum price for controlled drug cannabis items under the Misuse of Drugs Act1975.

Separating the four variables

Every claim about medicinal cannabis should be read through four separate lenses. When you mix them up, the evidence seems contradictory. When you separate them, most apparent conflicts dissolve.

1. Condition (what is being treated)

Evidence for chronic pain does not transfer to epilepsy, anxiety, or insomnia. A study that shows benefit for one condition says nothing about another. Always ask: which condition was studied?

2. Outcome (what was measured)

“Pain” can mean pain intensity at rest, pain on movement, sleep disruption, or quality of life. A preparation may improve one and not another. Always ask: which outcome was measured, and how was it measured (e.g., a0-10 scale, a questionnaire, a sleep diary)?

3. Preparation (which cannabinoids, which route, which dose)

Evidence for a high-CBD oil does not transfer to a high-THC flower, and evidence for an inhaled item does not transfer to an oral oil. The label must state: CBD content, THC content, ratio, form (flower/oil/capsule), and route (inhaled, sublingual, oral). If the evidence does not name these, it is not about the preparation you are holding.

4. Evidence quality, study design, and conflicts of interest

Distinguish systematic reviews and meta-analyses (highest), randomised controlled trials (high), open-label and observational studies (moderate), case reports (low), and marketing claims (not evidence). The New Zealand Ministry of Health and Medsafe do not rank items for efficacy; they regulate quality and access. Peer-reviewed clinical guidance, such as the NZ Formulary, is the most practical source for prescribers.

A high-quality trial for chronic pain will not necessarily predict results for epilepsy, anxiety, or sleep. The same preparation, dose, route, and outcome must be compared. Relevance to the New Zealand setting (item availability, legal status, patient population) matters as much as study quality.

Industry-funded studies tend to report larger effect sizes; check the funding source and whether the authors have received cannabis-industry payments. Government-funded or independent academic reviews are more reliable.

5. Cannabinoids are not interchangeable

A trial of a high-THC oil cannot be generalised to a high-CBD oil. The route (inhaled vs oral), the specific item, and the chemotype determine the result.

6. Outcome duration and safety

Evidence for short-term outcomes (e.g.,4 weeks of pain relief) cannot be extrapolated to years of use. Ask whether the study measured pain, sleep, function, quality of life, or anxiety. A change in one does not imply a change in the other.

Every study must be checked for how adverse events were reported. Mild sedation is common, but serious events are rare; in practice, the risk profile differs by preparation, route and dose. Do not drive or operate heavy machinery until you and your prescriber understand how a specific preparation affects you.

Source hierarchy

Use these sources in this order when evaluating a claim:

  • NZ Formulary and Healthify are the local gateways.
  • Medsafe approves items.
  • Peer-reviewed clinical guidance and systematic reviews from Cochrane, the US National Academies, or the Australian TGA are higher-quality sources than patient forums or vendor websites.

How to apply the method

When you or your clinician read a study, ask these questions in order:

  1. Is the preparation named with its CBD content, THC content, ratio, form and route?
  2. Is the dose specified?
  3. Is the outcome clinically meaningful (e.g., a30% pain reduction on a validated scale, not “felt better”)?
  4. Is the evidence quality stated (systematic review, RCT, observational, anecdote)?
  5. Is the study relevant to the New Zealand regulatory and clinical context?

If a claim lacks any of the first four, it is marketing, not evidence. Take the answers to a clinician; the clinician decides if a prescription is appropriate. This is not a prescription and does not replace a consultation.